Multiple Sclerosis
Conference Coverage
In Unexpected Finding, Clemastine Fumarate Linked to Worsening Symptoms in MS
Three patients demonstrated increased disability five times faster than their 18-month baseline, which triggered stoppage of the trial.
Conference Coverage
An Easy, Effective Solution to Exercise-Induced Heat Sensitivity in RRMS?
Compared with placebo, body temperature increase from baseline to exercise stoppage was significantly reduced with aspirin and with acetaminophen...
Conference Coverage
Not Even Secondary Endpoints Support BTK Inhibitor in Phase 3 MS Trial
Conference Coverage
Stem Cell Extension Study Reinforces Signal of Benefit for Progressive MS
At interim analysis, a stem cell extension study shows favorable clinical and biomarker effects for progressive MS.
Conference Coverage
The Power of Patient-Reported Outcomes Is Inhibited by Multiple Barriers
Patient-reported outcomes in multiple sclerosis (MS) matter, but remain underused due to multiple barriers.
Conference Coverage
Randomized Trial Confirms Prognostic Value of Neurofilament Light Chains in MS
ASCLEPIOS substudies find high sNfL levels at 3 and 12 months predictive of future CNS activity in patients with MS.
Literature Review
Frexalimab Promising for Relapsing Multiple Sclerosis
“In this trial, the MRI outcomes with frexalimab therapy were impressive but appear to be less complete than those with anti-CD20 agents, although...
Conference Coverage
Barriers to Remyelinating Drugs in MS Are Falling as Science Advances
“Once we understand the biology, we can turn barriers into opportunities.”
Conference Coverage
Is Migraine a Forerunner of Multiple Sclerosis?
“The inflammatory setting of the first MS relapse might be actually triggering the migraine.”
Literature Review
Seizure Risk Is Nearly Double in Patients With MS
Those with a progressive disease phenotype are at particularly high seizure risk.